Key Takeaways

  • Two independent studies support the safety, efficacy, and durability of Biovance 3L Ocular in both surgical and ocular surface disease applications.

  • In pterygium excision, the glueless, sutureless technique using Biovance 3L Ocular demonstrated no recurrences or significant complications while preserving conjunctiva and reducing surgical time.

  • Compared to single-layer DBM, Biovance 3L Ocular showed a statistically greater and longer-lasting reduction in corneal staining through 6 months

DefEYE announced the publication of two peer-reviewed articles showcasing the clinical utility of Biovance 3L Ocular, the only tri-layer decellularized basement membrane (DBM) designed for use in ocular surgery and ocular surface disease applications. The studies provide real-world data supporting the safety, efficacy, and durability of Biovance 3L Ocular in both surgical and therapeutic settings.

Study Highlights: Glueless, Sutureless Pterygium Surgery

The first publication, titled “A Retrospective Review of Glueless, Sutureless Pterygium Excision Using Biovance Triple-Layer Decellularized Amniotic Basement Membrane Tissue,” was authored by Marguerite McDonald, MD, and published in Ophthalmology and Therapy.1 The retrospective review evaluated outcomes following pterygium excision using Biovance 3L Ocular without sutures or glue.

Pterygium surgery has historically presented challenges, including recurrence risk, postoperative discomfort, extended steroid use, and inconsistent cosmetic outcomes.

“Managing pterygium can be challenging given the risks of recurrence, postoperative discomfort, prolonged steroid use, and variable cosmetic outcomes with traditional techniques,” said Dr. McDonald. “Glueless and sutureless pterygium excision using Biovance 3L Ocular decellularized basement membrane has become my preferred surgical approach, representing an important evolution from conjunctival autograft.”

Key findings from the study include:

  • The simplified, glueless and sutureless technique maintained excellent safety and efficacy

  • No reported recurrences, pyogenic granuloma, dellen, or infection

  • Preservation of conjunctiva, reduced surgical time, and effective clinical outcomes

  • Potential cost reduction in pterygium surgery while enhancing results in both routine and high-risk cases

The findings suggest that tri-layer DBM may offer a streamlined surgical alternative with strong clinical outcomes and reduced complication risk.

Study Highlights: Long-Term Outcomes in Ocular Surface Disease

The second publication, titled “Comparison of Effectiveness of Biovance Single and Triple Layer Decellularized Basement Membranes for Treatment of Ocular Surface Disease: A Retrospective Study,” was authored by Melanie Denton, OD, and published in Clinical Optometry.2 The study compared clinical outcomes between Biovance Single Layer DBM and Biovance 3L Ocular (Triple Layer DBM) in patients with moderate to severe dry eye disease (DED).

Corneal healing was evaluated over a 6-month period in patients receiving either product in conjunction with pressure patching.

“Both Biovance single- and triple-layer decellularized basement membranes demonstrated meaningful clinical improvement in corneal staining seen in moderate to severe dry eye at 3 months,” said Dr. Denton. “But the Biovance triple-layer membrane continued to show a statistically greater magnitude of clinical impact even out to 6 months post-placement. This enduring effect makes Biovance® 3L Ocular my go-to intervention when managing recalcitrant dry eyes.”

Key findings from the study include:

  • Statistically significant reductions in corneal fluorescein staining at both 3 and 6 months in both treatment groups

  • At 6 months, the reduction in corneal staining in the Biovance 3L Ocular group was statistically significantly greater than that observed in the single-layer Biovance group

  • Greater magnitude and duration of corneal staining improvement with Biovance 3L Ocular at both 3 and 6 months

  • Support for the long-term efficacy of multi-layered DBM in treating DED-related epithelial disease

References

1. McDonald M. A Retrospective Review of Glueless, Sutureless Pterygium Excision Using Biovance Triple-Layer Decellularized Amniotic Basement Membrane Tissue. Ophthalmol Ther. 2026 Jan 20.

2. Denton M. Comparison of Effectiveness of Biovance Single and Triple Layer Decellularized Basement Membranes for Treatment of Ocular Surface Disease: A Retrospective Study. Clin Optom (Auckl). 2026;18:1-8